SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more
SenzaGen AB (SENZA) - Net Assets
Latest net assets as of September 2025: Skr74.24 Million SEK
Based on the latest financial reports, SenzaGen AB (SENZA) has net assets worth Skr74.24 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr98.37 Million) and total liabilities (Skr24.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr74.24 Million |
| % of Total Assets | 75.47% |
| Annual Growth Rate | 45.4% |
| 5-Year Change | -19.62% |
| 10-Year Change | 108.24% |
| Growth Volatility | 576.29 |
SenzaGen AB - Net Assets Trend (2014–2024)
This chart illustrates how SenzaGen AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SenzaGen AB (2014–2024)
The table below shows the annual net assets of SenzaGen AB from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr86.64 Million | +28.15% |
| 2023-12-31 | Skr67.61 Million | -24.63% |
| 2022-12-31 | Skr89.70 Million | -18.63% |
| 2021-12-31 | Skr110.24 Million | +2.27% |
| 2020-12-31 | Skr107.79 Million | -19.68% |
| 2019-12-31 | Skr134.21 Million | +56.18% |
| 2018-12-31 | Skr85.94 Million | -14.92% |
| 2017-12-31 | Skr101.01 Million | +208.80% |
| 2016-12-31 | Skr32.71 Million | -21.38% |
| 2015-12-31 | Skr41.61 Million | +1929.61% |
| 2014-12-31 | Skr2.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SenzaGen AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11993.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr43.17 Million | 49.83% |
| Common Stock | Skr1.48 Million | 1.70% |
| Other Comprehensive Income | Skr6.19 Million | 7.14% |
| Other Components | Skr35.80 Million | 41.33% |
| Total Equity | Skr86.64 Million | 100.00% |
SenzaGen AB Competitors by Market Cap
The table below lists competitors of SenzaGen AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Forgame Holdings Limited
F:FH0
|
$9.77 Million |
|
Catskill Hudson Bancorp Inc
PINK:CSKL
|
$9.77 Million |
|
Etiler İnci Bufe Gida Sanayi ve Dis Ticaret AS
IS:ETILR
|
$9.77 Million |
|
Interwood-Xylemporia A.T.E.N.E.
AT:XYLEK
|
$9.77 Million |
|
23Andme Holding Co
NASDAQ:ME
|
$9.76 Million |
|
Cineline India Limited
NSE:CINELINE
|
$9.76 Million |
|
PT Puri Sentul Permai Tbk
JK:KDTN
|
$9.76 Million |
|
Vishwaraj Sugar Industries Limited
NSE:VISHWARAJ
|
$9.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SenzaGen AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 67,608,000 to 86,641,000, a change of 19,033,000 (28.2%).
- Net loss of 17,850,000 reduced equity.
- Share repurchases of 37,210,000 reduced equity.
- New share issuances of 37,210,000 increased equity.
- Other comprehensive income increased equity by 2,466,000.
- Other factors increased equity by 34,417,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-17.85 Million | -20.6% |
| Share Repurchases | Skr37.21 Million | -42.95% |
| Share Issuances | Skr37.21 Million | +42.95% |
| Other Comprehensive Income | Skr2.47 Million | +2.85% |
| Other Changes | Skr34.42 Million | +39.72% |
| Total Change | Skr- | 28.15% |
Book Value vs Market Value Analysis
This analysis compares SenzaGen AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.70x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.17 | Skr4.78 | x |
| 2015-12-31 | Skr3.75 | Skr4.78 | x |
| 2016-12-31 | Skr2.95 | Skr4.78 | x |
| 2017-12-31 | Skr6.53 | Skr4.78 | x |
| 2018-12-31 | Skr5.53 | Skr4.78 | x |
| 2019-12-31 | Skr8.30 | Skr4.78 | x |
| 2020-12-31 | Skr5.05 | Skr4.78 | x |
| 2021-12-31 | Skr4.58 | Skr4.78 | x |
| 2022-12-31 | Skr3.72 | Skr4.78 | x |
| 2023-12-31 | Skr2.80 | Skr4.78 | x |
| 2024-12-31 | Skr3.17 | Skr4.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SenzaGen AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.94%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.29x
- Recent ROE (-20.60%) is below the historical average (-20.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 13.70% | 16.13% | 0.36x | 2.38x | Skr70.70K |
| 2015 | -6.87% | -163.44% | 0.04x | 1.09x | Skr-7.02 Million |
| 2016 | -27.34% | -1795.58% | 0.01x | 1.07x | Skr-12.21 Million |
| 2017 | -12.86% | -1126.97% | 0.01x | 1.08x | Skr-23.09 Million |
| 2018 | -18.72% | -805.71% | 0.02x | 1.05x | Skr-24.68 Million |
| 2019 | -37.43% | -1844.24% | 0.02x | 1.07x | Skr-63.66 Million |
| 2020 | -25.34% | -343.24% | 0.07x | 1.03x | Skr-38.09 Million |
| 2021 | -28.43% | -203.26% | 0.12x | 1.21x | Skr-42.37 Million |
| 2022 | -27.77% | -59.64% | 0.35x | 1.34x | Skr-33.88 Million |
| 2023 | -32.68% | -44.31% | 0.51x | 1.44x | Skr-28.86 Million |
| 2024 | -20.60% | -30.94% | 0.52x | 1.29x | Skr-26.51 Million |
Industry Comparison
This section compares SenzaGen AB's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $158,330,786
- Average return on equity (ROE) among peers: -24.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SenzaGen AB (SENZA) | Skr74.24 Million | 13.70% | 0.33x | $9.76 Million |
| AroCell AB (AROC) | $-592.00K | 0.00% | 0.00x | $6.76 Million |
| Devyser Diagnostics AB (DVYSR) | $431.44 Million | -10.65% | 0.16x | $80.25 Million |
| Genetic Analysis AS (GEAN) | $44.14 Million | -64.05% | 0.46x | $1.89 Million |